Scholarlink

<p>Hydroxyapatite (HAp) nanoparticles are gaining attention as potential drug delivery systems for Alzheimer’s Disease (AD) because of their compatibility with biological systems, stability, and adaptable surfaces. Their small size facilitates effective drug encapsulation and controlled release, while surface alterations with ligands or antibodies enable precise targeting of delivery to the blood–brain barrier (BBB) and to areas affected by amyloid-beta (Aβ) plaques and tau accumulations. HAp nanoparticles are capable of transporting anti-amyloid, anti-tau, and neuroprotective drugs, which increases therapeutic levels and reduces systemic adverse effects. Research shows that HAp nanoparticles can pass through the BBB using adsorptive-mediated and receptor-mediated transcytosis, and methods such as temporarily opening tight junctions or modifying surface charges can further improve their permeability. Drugs can be integrated via co-precipitation, adsorption, or encapsulation techniques, often allowing for pH-responsive release in the acidic environment of diseased brain tissue. Nevertheless, there are still obstacles to address regarding the scalability of production, stability and clearance in living organisms, and the long-term compatibility and safety in neural tissue.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Hydroxyapatite nanoparticles as a vehicle for drug delivery approach in Alzheimer’s disease

  • 期刊论文

  • 发表日期：

    2026年2月17日

查看全文
  • S. M. Osaid Rizvi,
  • Akrish Thakur,
  • Sakshi Sharma,
  • Harsimran Kaur,
  • Sukhmanpreet Kaur,
  • Pallavi Dan

摘要

Hydroxyapatite (HAp) nanoparticles are gaining attention as potential drug delivery systems for Alzheimer’s Disease (AD) because of their compatibility with biological systems, stability, and adaptable surfaces. Their small size facilitates effective drug encapsulation and controlled release, while surface alterations with ligands or antibodies enable precise targeting of delivery to the blood–brain barrier (BBB) and to areas affected by amyloid-beta (Aβ) plaques and tau accumulations. HAp nanoparticles are capable of transporting anti-amyloid, anti-tau, and neuroprotective drugs, which increases therapeutic levels and reduces systemic adverse effects. Research shows that HAp nanoparticles can pass through the BBB using adsorptive-mediated and receptor-mediated transcytosis, and methods such as temporarily opening tight junctions or modifying surface charges can further improve their permeability. Drugs can be integrated via co-precipitation, adsorption, or encapsulation techniques, often allowing for pH-responsive release in the acidic environment of diseased brain tissue. Nevertheless, there are still obstacles to address regarding the scalability of production, stability and clearance in living organisms, and the long-term compatibility and safety in neural tissue.